RU2370490C2 - ПРОИЗВОДНЫЕ АРИЛАНИЛИНА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА - Google Patents

ПРОИЗВОДНЫЕ АРИЛАНИЛИНА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА Download PDF

Info

Publication number
RU2370490C2
RU2370490C2 RU2006129312/04A RU2006129312A RU2370490C2 RU 2370490 C2 RU2370490 C2 RU 2370490C2 RU 2006129312/04 A RU2006129312/04 A RU 2006129312/04A RU 2006129312 A RU2006129312 A RU 2006129312A RU 2370490 C2 RU2370490 C2 RU 2370490C2
Authority
RU
Russia
Prior art keywords
compound
hydroxy
alkylenyl
hydrogen
formula
Prior art date
Application number
RU2006129312/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2006129312A (ru
Inventor
Роберт Мюрей МАККИННЕЛЛ (US)
Роберт Мюрей МАККИННЕЛЛ
Джон Р. ДЖЕКОБСЕН (US)
Джон Р. ДЖЕКОБСЕН
Син Дж. ТРЭПП (US)
Син Дж. ТРЭПП
Дайсуке Роланд САИТО (US)
Дайсуке Роланд САИТО
Original Assignee
Тереванс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тереванс, Инк. filed Critical Тереванс, Инк.
Publication of RU2006129312A publication Critical patent/RU2006129312A/ru
Application granted granted Critical
Publication of RU2370490C2 publication Critical patent/RU2370490C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2006129312/04A 2004-01-12 2005-01-11 ПРОИЗВОДНЫЕ АРИЛАНИЛИНА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА RU2370490C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53578404P 2004-01-12 2004-01-12
US60/535,784 2004-01-12

Publications (2)

Publication Number Publication Date
RU2006129312A RU2006129312A (ru) 2008-02-20
RU2370490C2 true RU2370490C2 (ru) 2009-10-20

Family

ID=34806964

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006129312/04A RU2370490C2 (ru) 2004-01-12 2005-01-11 ПРОИЗВОДНЫЕ АРИЛАНИЛИНА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА

Country Status (19)

Country Link
US (3) US7622467B2 (https=)
EP (1) EP1706371B1 (https=)
JP (1) JP5041814B2 (https=)
CN (1) CN1910137B (https=)
AR (1) AR047098A1 (https=)
AT (1) ATE504559T1 (https=)
AU (1) AU2005206510A1 (https=)
BR (1) BRPI0506823A (https=)
CA (1) CA2551821A1 (https=)
DE (1) DE602005027307D1 (https=)
ES (1) ES2364450T3 (https=)
IL (1) IL176549A0 (https=)
MA (1) MA28304A1 (https=)
NO (1) NO20063620L (https=)
NZ (1) NZ548196A (https=)
RU (1) RU2370490C2 (https=)
TW (1) TW200531692A (https=)
WO (1) WO2005070872A1 (https=)
ZA (1) ZA200605720B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200134B1 (en) 1998-01-20 2001-03-13 Kerr Corporation Apparatus and method for curing materials with radiation
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US7182597B2 (en) 2002-08-08 2007-02-27 Kerr Corporation Curing light instrument
TW200526547A (en) * 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
CN1984876A (zh) * 2004-06-03 2007-06-20 施万制药 二胺类β2肾上腺素能受体激动剂
WO2006014704A1 (en) * 2004-07-21 2006-02-09 Theravance, Inc. DIARYL ETHER β2 ADRENERGIC RECEPTOR AGONISTS
WO2006031556A2 (en) * 2004-09-10 2006-03-23 Theravance. Inc. Amidine substituted aryl aniline compounds
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
NZ556335A (en) * 2005-01-11 2009-07-31 Glaxo Group Ltd Cinnamate salts of a beta-2 adrenergic agonist
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US8113830B2 (en) 2005-05-27 2012-02-14 Kerr Corporation Curing light instrument
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
JP2009504624A (ja) 2005-08-08 2009-02-05 アージェンタ ディスカバリー リミテッド ビシクロ［２．２．１］ヘプタ−７−イルアミン誘導体およびその使用
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
TW200745067A (en) * 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
PT2322525E (pt) 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
UY31905A (es) 2008-06-18 2010-01-29 Astrazeneca Ab Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
US8236786B2 (en) * 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
MX2011007036A (es) 2008-12-30 2011-07-20 Pulmagen Therapeutics Inflammation Ltd Compuestos de sulfonamida para el tratamiento de trastornos respiratorios.
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
WO2011048409A1 (en) 2009-10-20 2011-04-28 Astrazeneca Ab Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
CN118416038B (zh) * 2024-04-28 2024-11-12 中国海洋大学 2-(2-甲基丙氧基)苯胺在制备治疗炎症性疾病的药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2095344C1 (ru) * 1991-11-20 1997-11-10 Санкио Компани Лимитед Производные 1-амино-2-замещенного фенилэтанола, способ их получения (варианты)
WO2002000622A2 (en) * 2000-06-27 2002-01-03 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
WO2003042160A1 (en) * 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
WO2003042164A1 (en) * 2001-11-13 2003-05-22 Theravance, Inc Aryl aniline beta-2 adrenergic receptor agonists
WO2004002939A2 (en) * 2002-06-27 2004-01-08 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE630296A (https=) 1962-03-31
AT310146B (de) 1971-04-26 1973-09-25 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen N,N'-Bis-(β-hydroxyaryläthyl)-diaminoalkanen und deren Säureadditionssalzen
CH545764A (https=) 1971-07-27 1974-02-15
BE794414A (fr) 1972-01-25 1973-07-23 Sandoz Sa Nouveaux amino-alcools, leur preparation et leur application comme medicament
FR2266497B1 (https=) 1974-04-03 1977-11-04 Roussel Uclaf
JPS5913510B2 (ja) 1975-12-26 1984-03-30 オオツカセイヤク カブシキガイシヤ カルボスチリルユウドウタイノセイゾウホウ
JPS5283619A (en) 1976-01-01 1977-07-12 Yamanouchi Pharmaceut Co Ltd Alpha-substituted aminomethyl benzyl alcohol derivative
JPS609713B2 (ja) 1976-10-08 1985-03-12 大塚製薬株式会社 カルボスチリル誘導体
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GB8507942D0 (en) 1985-03-27 1985-05-01 Beecham Group Plc Compounds
EP0233686A3 (en) 1986-01-11 1989-05-03 Beecham Group Plc Bis phenyl ethanol amines and bis phenyoxypropanolamines having a beta-agonist activity
US5223614A (en) * 1987-12-19 1993-06-29 Boehringer Ingelheim Gmbh New quaternary ammonium compounds, their preparation and use
US4894219A (en) 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
US5434304A (en) * 1990-09-26 1995-07-18 Aktiebolaget Astra Process for preparing formoterol and related compounds
GB9405019D0 (en) * 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
US6075040A (en) * 1996-09-05 2000-06-13 Eli Lilly And Company Selective β3 adrenergic agonists
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
GB9713819D0 (en) * 1997-06-30 1997-09-03 Glaxo Group Ltd Method of reducing the systemic effects of compounds
US6713651B1 (en) * 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20020143034A1 (en) * 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
WO2001007026A2 (en) 1999-07-22 2001-02-01 Eli Lilly And Company Improved method of treating type ii diabetes and obesity
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
SK15382002A3 (sk) * 2000-04-27 2003-03-04 Boehringer Ingelheim Pharma Kg Betamimetiká, farmaceutický prostriedok s ich obsahom a ich použitie
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
WO2002038544A2 (en) * 2000-11-10 2002-05-16 Eli Lilly And Company 3-substituted oxindole beta 3 agonists
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US7144908B2 (en) * 2001-03-08 2006-12-05 Glaxo Group Limited Agonists of beta-adrenoceptors
ES2296923T3 (es) * 2001-03-22 2008-05-01 Glaxo Group Limited Derivados formanilidas como agonistas del adrenorreceptor beta2.
KR20090057477A (ko) 2001-09-14 2009-06-05 글락소 그룹 리미티드 호흡기 질환 치료용 펜에탄올아민 유도체
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
JP2005523920A (ja) 2002-04-25 2005-08-11 グラクソ　グループ　リミテッド フェネタノールアミン誘導体
WO2003099764A1 (en) * 2002-05-28 2003-12-04 Theravance, Inc. ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
AR040661A1 (es) * 2002-07-26 2005-04-13 Theravance Inc Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
EP1622875B1 (en) * 2003-05-08 2009-12-02 Theravance, Inc. Crystalline forms of an arylaniline beta-2 adrenergic receptor agonist
US7556785B2 (en) * 2003-05-12 2009-07-07 United Phosphorus, Ltd. Apparatus and method for rapid and continuous generation of phosphine gas
TW200510277A (en) * 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
TW200526547A (en) * 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
CN1984876A (zh) * 2004-06-03 2007-06-20 施万制药 二胺类β2肾上腺素能受体激动剂
WO2006014704A1 (en) * 2004-07-21 2006-02-09 Theravance, Inc. DIARYL ETHER β2 ADRENERGIC RECEPTOR AGONISTS
WO2006031556A2 (en) * 2004-09-10 2006-03-23 Theravance. Inc. Amidine substituted aryl aniline compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2095344C1 (ru) * 1991-11-20 1997-11-10 Санкио Компани Лимитед Производные 1-амино-2-замещенного фенилэтанола, способ их получения (варианты)
WO2002000622A2 (en) * 2000-06-27 2002-01-03 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
WO2003042160A1 (en) * 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
WO2003042164A1 (en) * 2001-11-13 2003-05-22 Theravance, Inc Aryl aniline beta-2 adrenergic receptor agonists
US6670376B1 (en) * 2001-11-13 2003-12-30 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
WO2004002939A2 (en) * 2002-06-27 2004-01-08 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives

Also Published As

Publication number Publication date
DE602005027307D1 (de) 2011-05-19
NZ548196A (en) 2009-08-28
AU2005206510A1 (en) 2005-08-04
KR20070000466A (ko) 2007-01-02
BRPI0506823A (pt) 2007-05-29
IL176549A0 (en) 2006-10-31
CA2551821A1 (en) 2005-08-04
RU2006129312A (ru) 2008-02-20
AR047098A1 (es) 2006-01-04
US20120071654A1 (en) 2012-03-22
US7622467B2 (en) 2009-11-24
ATE504559T1 (de) 2011-04-15
EP1706371B1 (en) 2011-04-06
CN1910137B (zh) 2010-05-26
ES2364450T3 (es) 2011-09-02
US20050159448A1 (en) 2005-07-21
MA28304A1 (fr) 2006-11-01
CN1910137A (zh) 2007-02-07
JP2007518738A (ja) 2007-07-12
WO2005070872A1 (en) 2005-08-04
EP1706371A1 (en) 2006-10-04
NO20063620L (no) 2006-10-06
US20100087410A1 (en) 2010-04-08
JP5041814B2 (ja) 2012-10-03
ZA200605720B (en) 2008-09-25
US7994165B2 (en) 2011-08-09
TW200531692A (en) 2005-10-01

Similar Documents

Publication Publication Date Title
RU2370490C2 (ru) ПРОИЗВОДНЫЕ АРИЛАНИЛИНА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА
US7402673B2 (en) Diamine β2 adrenergic receptor agonists
US7964730B2 (en) Amino-substituted ethylamino β2 adrenergic receptor agonists
US7566785B2 (en) Amidine substituted aryl aniline compounds
US20060019991A1 (en) Diaryl ether beta2 adrenergic receptor agonists
MXPA06007723A (en) Aryl aniline derivatives as beta2 adrenergic receptor agonists
HK1093486B (en) Amino-substituted ethylamino beta2 adrenergic receptor agonists
KR20060136436A (ko) 베타 2-아드레날린성 수용체 아고니스트로서의 아릴 아닐린유도체
KR20070022773A (ko) 디아민 베타 2(ß2) 아드레날린 수용체 아고니스트

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20110112